Crowley MJ , et al.. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. Ann Intern Med 2017; 166:191–200.
Chowdhury TA , et al.. Could metformin be used in patients with diabetes and advanced chronic kidney disease? Diabetes Obes Metab 2017; 19:156–161.
Lalau JD , et al.. Metformin and other antidiabetic agents in renal failure patients. Kidney Int 2015; 87:308–322.
Hung SC , et al.. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. Lancet Diabetes Endocrinol 2015; 3:605–614.
Sanchez-Rangel E , Inzucchi SE . Metformin: Clinical use in type 2 diabetes. Diabetologia 2017; 60:1586–1593.
Bailey CJ . Metformin: historical overview. Diabetologia. 2017; 60:1566–1576.
An H , He L . Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol 2016; 228:R97–R106.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837–853.
Introduction: Standards of Medical Care in Diabetes–2019. Diabetes Care 2019; 42:S1–S2.
Holman RR , et al.. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577–1589.
Foretz M , et al.. Metformin: From mechanisms of action to therapies. Cell Metab 2014; 20:953–966.
Inzucchi SE , et al.. Metformin in patients with type 2 diabetes and kidney disease: A systematic review. JAMA 2014; 312:2668–2675.
Eurich DT , et al.. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure. Circ Heart Fail 2013; 6:395–402.